{
  "docId": "019de075-c1ce-7016-922a-ee59c26b52e2",
  "docSlug": "7a9033616f2f52a3ff84a89721dd4a41",
  "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 23 slides",
  "authorId": "nuvectis-pharma",
  "authorName": "Nuvectis Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 23,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-c1ce-7016-922a-ee59c26b52e2/7",
  "deckHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2",
  "deckJsonHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2.json",
  "deckAnchorHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.96,
        "x": 0.03,
        "y": 0.238
      },
      "kind": "list",
      "text": "Precision Medicine Approach: Discovered at ICR, GCN2 kinase activator, ARID1a loss as sensitivity marker.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1f47bead-97b6-4daf-8bdf-f7f0eb6feff8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.96,
        "x": 0.03,
        "y": 0.415
      },
      "kind": "list",
      "text": "Focused Clinical & Regulatory Strategy: Fast Track Designation, high prevalence of ARID1a mutation (66% and 40%), rare in high grade serous.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f9f71db-195a-42e8-abfc-6db784a95b53",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.96,
        "x": 0.03,
        "y": 0.592
      },
      "kind": "list",
      "text": "Preclinical & Clinical Data: Tumor growth inhibition, ESMO/AACR presentations, Phase 1a biomarker induction.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea54a5ad-71bb-469f-ba8b-8ee3c1f54d62",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.96,
        "x": 0.03,
        "y": 0.769
      },
      "kind": "list",
      "text": "Phase 1b: Collaboration with ENGOT and GOG-F.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee6bd5bf-7f87-477a-be70-cc317070c55b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.42,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "NXP800 Key Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "11174c75-a7fe-42d0-8222-4ffe782fe94c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "f5359076-33bd-4477-b95a-b5524f2b7268",
      "evidence": "list/bullet: Focused Clinical & Regulatory Strategy: Fast Track Designation, high prevalence of ARID1a mutation (66% and 40%), rare in high grade serous.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 7,
      "beatId": "c1062702-11f0-40ee-8dcf-e049e6911d1a",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document presents Nuvectis Pharma's solution, including NXP800 and NXP900",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 22,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "e81cf698-f51d-4b2d-9877-cb9fc692efbb",
      "evidence": "The document presents the potential benefits of Nuvectis Pharma's pipeline",
      "position": 0,
      "objective": "Highlight the cost of inaction in oncology",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 20,
      "from": 7,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "e770d6a7-7a71-413e-a8f8-c45403042dac",
      "evidence": "The document presents data on the potential of NXP800 and NXP900",
      "position": 1,
      "objective": "Present Nuvectis Pharma's solution as a quick win and big bet",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}